Target prioritisation

Speaker: Fabrice Andre

F. Andre explains why target prioritisation is important and describes attempts for guidance on how to use genomic data in oncology. The goal is an evidence-based definition of which molecular alterations should lead to treatment decision in daily practice, which ones could lead to driving patients to phase I/II trials, and which ones should not be used for treatment decision.

Discussion points

  • In the spectrum of biology, what could be suitable target(s) for characterisation in oncology?
  • Why is target prioritisation one of the most critical steps in understanding the molecular biology of the disease and drug discovery?
  • How to distinguish and narrow candidate targets?
  • Some attempts of target prioritisation in oncology